Zura Bio (NASDAQ:ZURA - Get Free Report) will likely be issuing its Q2 2025 quarterly earnings data before the market opens on Tuesday, August 12th. Analysts expect the company to announce earnings of ($0.19) per share for the quarter.
Zura Bio (NASDAQ:ZURA - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.02). On average, analysts expect Zura Bio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Zura Bio Stock Down 3.2%
NASDAQ ZURA opened at $1.52 on Thursday. The business has a 50-day moving average price of $1.31 and a 200-day moving average price of $1.33. The firm has a market cap of $103.93 million, a price-to-earnings ratio of -2.17 and a beta of -0.06. Zura Bio has a twelve month low of $0.97 and a twelve month high of $5.07.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Zura Bio stock. Bank of America Corp DE increased its stake in shares of Zura Bio Limited (NASDAQ:ZURA - Free Report) by 31.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 41,222 shares of the company's stock after purchasing an additional 9,966 shares during the quarter. Bank of America Corp DE owned 0.06% of Zura Bio worth $103,000 at the end of the most recent quarter. Institutional investors own 61.14% of the company's stock.
Analyst Upgrades and Downgrades
Separately, Oppenheimer reduced their price objective on Zura Bio from $19.00 to $17.00 and set an "outperform" rating on the stock in a research note on Friday, May 9th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $14.33.
Check Out Our Latest Report on Zura Bio
About Zura Bio
(
Get Free Report)
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.
Featured Articles
Before you consider Zura Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zura Bio wasn't on the list.
While Zura Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
